Patents by Inventor Alyson J. Cobb

Alyson J. Cobb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8771673
    Abstract: A method of combating rheumatoid arthritis, comprising administering to a human subject in need thereof, an effective oral dose of a probiotic composition in an oral dose form including, as the only bacterial species therein, the bacterial species of Bacillus subtilis, Bacillus coagulans, and Enterococcus faecium. The initial occurrence, and progress of remission of the rheumatoid arthritis condition incident to such probiotic therapy, may be established and monitored by assay of rheumatoid factor and/or anti-CCP antibodies present in a blood sample of the human subject.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: July 8, 2014
    Assignee: Cobb & Associates
    Inventors: Mark L. Cobb, Alyson J. Cobb
  • Publication number: 20130022577
    Abstract: Compositions and methods for treatment or prophylaxis of a bipolar disorder disease state, in which the compositions include the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The compositions may be embodied in suitable dose forms such as capsules containing the microbial species in combination with a substrate for the microbial species, e.g., fructo-oligosaccharides, for oral administration according to a predetermined dosage schedule.
    Type: Application
    Filed: August 21, 2012
    Publication date: January 24, 2013
    Applicant: Cobb & Associates
    Inventors: Mark L. COBB, Alyson J. Cobb
  • Publication number: 20120244124
    Abstract: A method of combating rheumatoid arthritis, comprising administering to a human subject in need thereof, an effective oral dose of a probiotic composition in an oral dose form including, as the only bacterial species therein, the bacterial species of Bacillus subtilis, Bacillus coagulans, and Enterococcus faecium. The initial occurrence, and progress of remission of the rheumatoid arthritis condition incident to such probiotic therapy, may be established and monitored by assay of rheumatoid factor and/or anti-CCP antibodies present in a blood sample of the human subject.
    Type: Application
    Filed: June 5, 2012
    Publication date: September 27, 2012
    Applicant: COBB & ASSOCIATES
    Inventors: Mark L. Cobb, Alyson J. Cobb